Frontiers in Cellular Neuroscience
February 15, 2023
Cui-Hong Zhou, Xinxin Zhao, Xinxu Ma et al.
Introduction: Compelling evidence indicates that a single sub-anesthetic dose of (S)-ketamine elicits rapid and robust antidepressant effects. However, the underlying mechanisms behind the antidepressant effects of (S)-ketamine remain unclear. Methods: Here, using a chronic variable stress (CVS) model in mice, we analyzed changes inthe lipid compositions of the hippocampus and prefrontal cortex...
European Archives of Psychiatry and Clinical Neuroscience
February 14, 2023
Kenji Hashimoto
40 citations
Cognitive impairment has been observed in patients with various psychiatric disorders, including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BD). Although modern therapeutic drugs can improve certain symptoms (i.e., psychosis, depression) in these patients, these drugs have not been found to improve cognitive impairment. The N-methyl-D-aspartate receptor antagonist...
Frontiers in Neuroscience
February 2, 2023
Haiyan Liu, Chengyu Wang, Xiaofeng Lan et al.
Background Dysfunction of the amygdala is the core pathogenesis of major depressive disorder (MDD). However, it remains unclear whether ketamine treatment could modulate characteristics of amygdala-related networks. We aimed to explore the relationship between changes in the resting-state functional connectivity (RSFC) of the amygdala and the treatment of ketamine in MDD patients and to...
The Brown University Psychopharmacology Update
February 1, 2023
Results of a systematic review and meta‐analysis comprising six clinical trials suggest that electroconvulsive therapy (ECT) is more efficacious than ketamine in reducing the severity of depressive symptoms in patients with a major depressive episode. No significant between‐group differences in the prevalence of adverse events were observed. Results of the meta‐analysis were published online...
Neuropharmacology
February 1, 2023
Taro Kato
Conventional antidepressant medications act on monoaminergic systems and have important limitations, including a therapeutic delay of weeks to months and low rates of efficacy. Recently, clinical findings have indicated that ketamine, a dissociative anesthetic that blocks N-methyl-d-aspartate receptor channel activity, causes rapid and long-lasting antidepressant effects. Although the exact...
Pharmaceuticals
February 1, 2023
Agnieszka Pałucha-Poniewiera, B. Bobula, Anna Rafało-Ulińska
(S)-Ketamine is the first rapid-acting antidepressant drug (RAAD) introduced for the treatment of depression. However, research is still being carried out on the search for further RAADs that will be not only effective but also safe to use. Recent data have indicated that the combined administration of (R)-ketamine and the mGlu2/3 receptor antagonist LY341495 (mixRL) induces rapid and sustained...
Neuropharmacology
February 1, 2023
Yu-Jung Cheng, Chieh-Hsin Lin, Hsien-Yuan Lane
Studies have demonstrated the beneficial therapeutic effects of sarcosine, benzoate, and ketamine (including esketamine and arketamine) on depression. These drugs mainly act by modulating N-methyl-d-aspartate glutamate receptors (NMDARs) and reducing inflammation in the brain. Although ketamine, benzoate, and sarcosine act differently as the antagonists or coagonists of NMDARs, they all have...
Neuropharmacology
February 1, 2023
Shigeyuki Chaki, Mai Watanabe
The efficacy of currently available medications for depression is unsatisfactory, and that has spurred the development of novel antidepressants based on a hypothesis other than the monoamine hypothesis. Recent studies have revealed the importance of the glutamatergic system as a drug target for depression, and the validity of this hypothesis has been underpinned by the discovery of the...
Journal of Child and Adolescent Psychopharmacology
February 1, 2023
Alice Lineham, Victor J. Avila‐quintero, Michael H. Bloch et al.
20 citations
Objective: Ketamine has proven effective as a rapid-acting antidepressant agent. Several adult studies have investigated the association between ketamine's acute dissociative effects and depression response, but no studies have examined the association in adolescents with treatment-resistant depression (TRD). Methods: We conducted a secondary data analysis of 16 adolescent participants who...
Drug Discovery Today
February 1, 2023
J. Johnston, Maximillian Greenwald, Ioline D. Henter et al.
64 citations
Well-established animal models of depression have described a proximal relationship between stress and central nervous system (CNS) inflammation – a relationship mirrored in the peripheral inflammatory biomarkers of individuals with depression. Evidence also suggests that stress-induced proinflammatory states can contribute to the neurobiology of treatment-resistant depression. Interestingly,...